Efficacy of botulinum toxin in treating myofascial pain and occlusal force characteristics of masticatory muscles in bruxism

Jadhao, Varsha A; Lokhande, Nitin; Habbu, Shweta G; Sewane, Sagar; Dongare, Shailesh; Goyal, Neha

doi:10.4103/ijdr.ijdr_125_17

Cited by 49 publications

(38 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found 4 ongoing trials 12,23,33,40 that compared BTX-A versus placebo; these may contribute data in a future update of this review. We included 12 studies 1,7,10,16,17,24,26,35,37,39,51,54 in the review; 9 of these contributed data to meta-analyses (Fig 1).…”

Section: Search Resultsmentioning

confidence: 99%

“…Ten 1,7,16,17,24,26,37,39,51,53 of the 12 studies were parallel design RCTs and 2 10,34 were crossover trials. The 12 studies included 362 participants in total, mostly women (87.2%), between 26 and 69 years of age.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Nine 10,16,24,26,34,37,39,51,53 of the 12 RCTs (267 participants) compared BTX-A versus placebo. Eight trials 10,16,24,34,37,39,51,53 (237 participants) assessed temporomandibular pain reduction using a VAS (0−10 scale, higher values indicate more pain), while one trial 26 asked participants to fill out the RDC/TMD Axis II Biobehavioral Questionnaire to evaluate pain intensity. We pooled the results of 4 RCTs 10,16,24,39 in meta-analyses at 3 time points: 1, 3, and 6 months post-treatment.…”

Section: Comparison 1: Btx-a Versus Placebomentioning

confidence: 99%

See 2 more Smart Citations

Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis

Machado

Martimbianco

Bussadori

et al. 2020

The Journal of Pain

View full text Add to dashboard Cite

Section: Search Resultsmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Comparison 1: Btx-a Versus Placebomentioning

confidence: 99%

See 1 more Smart Citation

Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis

Machado

Martimbianco

Bussadori

et al. 2020

The Journal of Pain

View full text Add to dashboard Cite

“…The proposed therapeutic strategies can be listed as psychological approach, guidelines on sleep hygiene measures combined with relaxation methods, use of interocclusal devices, prescription of medication for pain control, electrical stimulation, physiotherapy, acupuncture and, more recently, use of botulinum toxin to control the contraction of the main muscles involved in the parafunction, decreasing muscular strength and pain [66,[74][75][76].…”

Section: Therapeutic Strategies To Control Bruxismmentioning

confidence: 99%

Oral Parafunction - Aetiology, Implications and Relation to Orthodontic Treatment

Corradi¹,

Avelar²

2020

Maxillofacial Surgery and Craniofacial Deformity - Practices and Updates

View full text Add to dashboard Cite

Oral parafunction can be defined as an extra-functional action of certain components of the stomatognathic system. The automation of this kind of occurrence that persists in the form of a reflex arc is a denominated habit. The oral parafunctional habits are described as the action of clenching or grinding teeth (bruxism), among others. This work approached bruxism due to its clinical importance. To evaluate the predisposing factors to the development of oral parafunction, the orthodontist should have updated knowledge of the whole process of the phenomenon of bruxism. The purposes of this chapter were about the comprehension of the neurophysiology of bruxism and also about the capacity of structural adaptation of the components of the stomatognathic system, the analysis of its aetiological factors, as well as its implications on the structures of the masticatory system, and the verification of the relation between bruxism and the orthodontic treatment. In conclusion, the nature of that oral habit is multifactorial, which implies extrafunctional demand of neurophysiological mechanisms, whose effects are installed from the rupture of the structural limit of the adaptive capacity of the stomatognathic system, peculiar to each individual. The performance of orthodontic treatment is not related to the development of bruxism.

show abstract

“…Furthermore, pain intensity can be assessed by a visual analog scale (VAS). 5 There are several treatment approaches for this disease, but the common target being muscle relaxation. Studies suggest that the treatment can be conducted with oral appliance, which seems to be effective in reducing SB activity, with a better resolution with devices that provide a large extension of the mandibular advancement.…”

Section: Introductionmentioning

confidence: 99%

<p>The Current Trend in Management of Bruxism and Chronic Pain: An Overview of Systematic Reviews</p>

Bussadori¹,

Motta²,

Horliana³

et al. 2020

JPR

View full text Add to dashboard Cite

Bruxism, specifically sleep bruxism (SB), is a worldwide discussed topic in the literature; however, there is insufficient evidence to define and support a standard approach for the treatment of SB. The purpose of this overview was to map the evidence from systematic reviews (SR), examining the effects of interventions to improve chronic pain related to bruxism. The methodological quality of SRs was assessed using the AMSTAR-2 tool. We conducted a comprehensive literature search in April 2020, in the following databases: Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE, LILACS, BBO, and Epistemonikos. Nine SRs with critically low to high methodological quality were included. Considering the main findings, botulinum toxin type A (BTX-A) showed a significant pain and sleep bruxism frequency reduction when compared to placebo or conventional treatment (behavioral therapy, occlusal splints, and drugs), after 6 and 12 months. Occlusal splints combined to muscle massage showed some benefit in pain reduction. There was no difference in pain and bruxism frequency between biofeedback therapy and an inactive control group. Regarding drug therapy, there is no difference when amitriptyline, bromocriptine, clonidine, propranolol, and levodopa were compared to placebo. In conclusion, there is some evidence to support the use of occlusal splints plus massage, and BTX-A to reduce chronic pain related to SB. No evidence was provided to support the recommendation of biofeedback therapy and drug therapy. There is still a need for more methodologically rigorous randomized clinical trials (RCT) to be conducted on the efficacy and safety of different therapies for SB.

show abstract

Efficacy of botulinum toxin in treating myofascial pain and occlusal force characteristics of masticatory muscles in bruxism

Abstract: Results from the present study supported the efficacy of BTX-A to reduce myofascial pain symptoms in bruxers, and effective in reducing the occlusal force.

Cited by 49 publications

References 1 publication

Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis

Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis

Oral Parafunction - Aetiology, Implications and Relation to Orthodontic Treatment

<p>The Current Trend in Management of Bruxism and Chronic Pain: An Overview of Systematic Reviews</p>

Contact Info

Product

Resources

About